Drug concentration heterogeneity facilitates the evolution of drug resistance

被引:198
作者
Kepler, TB [1 ]
Perelson, AS
机构
[1] N Carolina State Univ, Dept Stat, Biomath Program, Raleigh, NC 27695 USA
[2] Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA
关键词
sanctuary sites; HIV;
D O I
10.1073/pnas.95.20.11514
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Pathogenic microorganisms use Darwinian processes to circumvent attempts at their control through chemotherapy In the case of HIV-1 infection, in which drug resistance is a continuing problem, we show that in one-compartment systems, there is a relatively narrow window of drug concentrations that allows evolution of resistant variants. When the system is enlarged to two spatially distinct compartments held at different drug concentrations with transport of virus between them, the range of average drug concentrations that allow evolution of resistance is significantly increased. For high average drug concentrations, resistance is very unlikely to arise without spatial heterogeneity, We argue that a quantitative understanding of the role played by heterogeneity in drug levels and pathogen transport is crucial for attempts to control re-emergent infectious disease.
引用
收藏
页码:11514 / 11519
页数:6
相关论文
共 36 条
[1]   Virus dynamics and drug therapy [J].
Bonhoeffer, S ;
May, RM ;
Shaw, GM ;
Nowak, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (13) :6971-6976
[2]  
Bonhoeffer S, 1997, P ROY SOC B-BIOL SCI, V264, P631
[3]   HIV-1: Gambling on the evolution of drug resistance? [J].
Brown, AJL ;
Richman, DD .
NATURE MEDICINE, 1997, 3 (03) :268-271
[4]   Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy [J].
Chun, TW ;
Stuyver, L ;
Mizell, SB ;
Ehler, LA ;
Mican, JAM ;
Baseler, M ;
Lloyd, AL ;
Nowak, MA ;
Fauci, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (24) :13193-13197
[5]   HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].
COFFIN, JM .
SCIENCE, 1995, 267 (5197) :483-489
[6]   IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].
CONDRA, JH ;
SCHLEIF, WA ;
BLAHY, OM ;
GABRYELSKI, LJ ;
GRAHAM, DJ ;
QUINTERO, JC ;
RHODES, A ;
ROBBINS, HL ;
ROTH, E ;
SHIVAPRAKASH, M ;
TITUS, D ;
YANG, T ;
TEPPLER, H ;
SQUIRES, KE ;
DEUTSCH, PJ ;
EMINI, EA .
NATURE, 1995, 374 (6522) :569-571
[7]   TREATMENT WITH LAMIVUDINE, ZIDOVUDINE, OR BOTH IN HIV-POSITIVE PATIENTS WITH 200 TO 500 CD4+ CELLS PER CUBIC MILLIMETER [J].
ERON, JJ ;
BENOIT, SL ;
JEMSEK, J ;
MACARTHUR, RD ;
SANTANA, J ;
QUINN, JB ;
KURITZKES, DR ;
FALLON, MA ;
RUBIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1662-1669
[8]   SPECTRUM OF DISEASE IN PERSONS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN THE UNITED-STATES [J].
FARIZO, KM ;
BUEHLER, JW ;
CHAMBERLAND, ME ;
WHYTE, BM ;
FROELICHER, ES ;
HOPKINS, SG ;
REED, CM ;
MOKOTOFF, ED ;
COHN, DL ;
TROXLER, S ;
PHELPS, AF ;
BERKELMAN, RL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (13) :1798-1805
[9]   Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [J].
Finzi, D ;
Hermankova, M ;
Pierson, T ;
Carruth, LM ;
Buck, C ;
Chaisson, RE ;
Quinn, TC ;
Chadwick, K ;
Margolick, J ;
Brookmeyer, R ;
Gallant, J ;
Markowitz, M ;
Ho, DD ;
Richman, DD ;
Siliciano, RF .
SCIENCE, 1997, 278 (5341) :1295-1300
[10]   QUASI-SPECIES DYNAMICS AND THE EMERGENCE OF DRUG-RESISTANCE DURING ZIDOVUDINE THERAPY OF HIV-INFECTION [J].
FROST, SDW ;
MCLEAN, AR .
AIDS, 1994, 8 (03) :323-332